TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07192107: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB042C for Injection in Patients With Advanced Solid Tumors

Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07192107 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07192107 Rescue Dossier →